Clinical Value of Eukaryotic Elongation Factor 2 (eEF2) in Non-small Cell Lung Cancer Patients |
Sun, Hong-Gang
(Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
Dong, Xue-Jun (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Lu, Tao (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Yang, Ming-Feng (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Wang, Xing-Mu (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) |
1 | Adcock IM, Caramori G, Barnes PJ (2011)..Chronic obstructive pulmonary disease and lung cancer: new molecular insights..Respiration, 81, 265-84. DOI ScienceOn |
2 | Chen CY, Fang HY, Chiou SH, et al (2011). Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci, 102, 1582-9. DOI ScienceOn |
3 | Hensing TA, Salgia R (2013). Molecular biomarkers for future screening of lung cancer. J Surg Oncol, 108, 327-33. DOI ScienceOn |
4 | Karp DD, Lee SJ, Keller SM, et al (2013). Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597. J Clin Oncol, 9, 1-12 |
5 | Leprivier G, Remke M, Rotblat B, et al (2013). The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell, 153, 1064-79. DOI ScienceOn |
6 | Liang J, Qian Y, Xu D, et al (2013). Serum tumor markers, hypoxia-inducible factor-1 HIF-1 and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention. Asian Pac J Cancer Prev, 14, 3851-4. DOI ScienceOn |
7 | Massion PP, Carbone DP (2003).The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res, 4, 1-15. DOI |
8 | Nakamura J, Aoyagi S, Nanchi I, et al (2009). Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol, 34, 1181-9. |
9 | Siegel R, Naishadham D, Jemal A (2012). Cancer Journal for Clinicians. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |